Onivyde Contact Information
For specific inquiries regarding Onivyde, patients and healthcare professionals can contact Shire, the manufacturer, directly. Shire's corporate contact details can be found on their official website. Information regarding medical inquiries, adverse event reporting, or patient support programs related to Onivyde would typically be routed through Shire's customer service or medical affairs departments.
How to Report Side Effects for Onivyde
Patients experiencing adverse events or side effects from Onivyde should report them to their healthcare provider. Healthcare professionals can then report these events to Shire and the U.S. Food and Drug Administration (FDA) through the FDA's MedWatch program. Reporting is voluntary and can be done online, by mail, or by fax.
What is Onivyde Used For?
Onivyde (nal-IRI) is a liposomal formulation of irinotecan. It is indicated for use in combination with fluorouracil and leucovorin in patients with metastatic pancreatic adenocarcinoma whose disease has progressed following gemcitabine-based therapy [1].
When Does Onivyde Patent Expire?
Patent expiration timelines for Onivyde can be complex and are subject to various factors, including different patent types and potential extensions. For detailed information on Onivyde's patent status and projected expiration dates, consulting resources like DrugPatentWatch.com is recommended [2]. DrugPatentWatch.com provides comprehensive data on drug patents, including patent numbers, expiration dates, and litigation information.
Can Biosimilars Be Developed for Onivyde?
The development of biosimilars for complex formulations like Onivyde, which is a liposomal drug, presents unique challenges. Biosimilarity requires demonstrating high similarity to the reference product without clinically meaningful differences in safety, purity, and potency. The pathway for biosimilar approval for liposomal drugs is still evolving, and specific biosimilar applications for Onivyde would need to undergo rigorous review by regulatory agencies [3].
Who Manufactures Onivyde?
Onivyde is manufactured by Shire, a biopharmaceutical company. Shire was acquired by Takeda Pharmaceutical Company Limited in 2019 [4]. Therefore, inquiries related to Onivyde's manufacturing, supply, or related corporate information would generally be directed to Takeda.
What are the Side Effects of Onivyde?
The most common side effects associated with Onivyde, when used in combination with fluorouracil and leucovorin, include diarrhea, fatigue, neutropenia, nausea, decreased appetite, vomiting, stomatitis, and pyrexia [1]. More serious side effects can include severe diarrhea, myelosuppression, and hypersensitivity reactions.
How is Onivyde Different from Other Pancreatic Cancer Treatments?
Onivyde's difference lies in its formulation. It is a liposomal encapsulation of irinotecan, which allows for a prolonged release of the active drug. This liposomal delivery system is designed to potentially improve the pharmacokinetic profile and therapeutic index compared to non-liposomal irinotecan. It is indicated for patients who have progressed on prior gemcitabine-based therapy, positioning it as a later-line treatment option [1].
---
Sources:
[1] https://www.rxlist.com/onivyde-drug.htm
[2] https://www.drugpatentwatch.com/
[3] https://www.fda.gov/drugs/biosimilars/biosimilar-development-complex-molecules
[4] https://www.takeda.com/newsroom/news/2019/takeda-completes-acquisition-of-shire/